Researchers at Mount Sinai have developed a game-changing approach to treating severe gut infections: engineered bacterial therapy that could be mass-produced far more easily than current treatments.

The breakthrough centers on recurrent C. difficile infections, a debilitating condition that often strikes after antibiotics wipe out the gut's beneficial bacteria. While fecal microbiota transplants have helped many patients, they're difficult to standardize and scale. This new manufacturing platform creates targeted mixtures of beneficial bacteria in a controlled, reproducible way—opening doors for patients who currently lack access to life-changing treatment. Read the full story →

Today's takeaway: Science is making cutting-edge microbiome therapies accessible to millions who need them most.